632
Views
4
CrossRef citations to date
0
Altmetric
HEMATOLOGICAL MALIGNANCY

A mutational and expressional analysis of DNMT3A in acute myeloid leukemia cytogenetic subgroups

, , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jia Gu, Zhiqiong Wang, Min Xiao, Xia Mao, Li Zhu, Ying Wang & Wei Huang. (2017) Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib. Cancer Biology & Therapy 18:11, pages 843-849.
Read now

Articles from other publishers (3)

Na Lin, Wei Fu, Chen Zhao, Bixin Li, Xiaojing Yan & Yan Li. (2017) Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia. Biochemical and Biophysical Research Communications 494:1-2, pages 270-277.
Crossref
Weijing Li, Lei Cui, Chao Gao, Shuguang Liu, Xiaoxi Zhao, Ruidong Zhang, Huyong Zheng, Minyuan Wu & Zhigang Li. (2017) DNMT3A mutations in Chinese childhood acute myeloid leukemia. Medicine 96:31, pages e7620.
Crossref
D. Zare‐Abdollahi, S. Safari, A. Movafagh, M. Ghadiani, M. Tabarraee, S. Riazi‐Isfahani, S. Gorji, L. Keyvan & L. Gachkar. (2016) Expression analysis of BECN 1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities . International Journal of Laboratory Hematology 38:2, pages 125-132.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.